Helga B. Salvesen

Helga B. Salvesen

Auto-generated profile, based on publicly available information

Helga B. Salvesen

Department of Obstetrics and Gynaecology; Haukeland University Hospital; Bergen Norway

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2013 in Nature
Verified
Journal Article
Closed access
PDF file
AOAkinyemi I. Ojesina
Akinyemi I. Ojesina
LLLee Lichtenstein
Lee Lichtenstein
SFSamuel S. Freeman
Samuel S. Freeman
CPChandra Sekhar Pedamallu
Chandra Sekhar Pedamallu
IIIvan Imaz-Rosshandler
Ivan Imaz-Rosshandler
MMMatthew Meyerson
Matthew Meyerson

24 March 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HSH. B. Salvesen
H. B. Salvesen
SCS. L. Carter
S. L. Carter
MMM. Mannelqvist
M. Mannelqvist
ADAmit Dutt
Amit Dutt
GGG. Getz
G. Getz
RBR. Beroukhim
R. Beroukhim
Although 75% of endometrial cancers are treated at an early stage, 15% to 20% of these recur. We performed an integrated analysis of genome-wide expression and copy-number data for primary endometrial carcinomas with extensive clinical and histopathological data to detect features predictive of recurrent disease. Unsupervised analysis of the expression data distinguished 2 major clusters with strikingly different phenotypes, including significant differences in disease-free survival. To identify possible mechanisms for these differences, we performed a global genomic survey of amplifications, deletions, and loss of heterozygosity, which identified 11 significantly amplified and 13 significantly deleted regions. Amplifications of 3q26.32 harboring the oncogenePIK3CAwere associated with poor prognosis and segregated with the aggressive transcriptional cluster. Moreover, samples withPIK3CAamplification carried signatures associated with in vitro activation of PI3 kinase (PI3K), a signature that was shared by aggressive tumors withoutPIK3CAamplification. Tumors with loss ofPTENexpression orPIK3CAoverexpression that did not havePIK3CAamplification also shared the PI3K activation signature, high protein expression of the PI3K pathway member STMN1, and an aggressive phenotype in test and validation datasets. However, mutations ofPTENorPIK3CAwere not associated with the same expression profile or aggressive phenotype. STMN1 expression had independent prognostic value. The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.

1 August 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
HSHelga B Salvesen
Helga B Salvesen
IHIngfrid Salvesen Haldorsen
Ingfrid Salvesen Haldorsen
JTJone Trovik
Jone Trovik

25 October 2012 in British Journal of Cancer
Verified
Journal Article
Open access
EBE Birkeland
E Birkeland
EWE Wik
E Wik
SMS Mjøs
S Mjøs
EHE A Hoivik
E A Hoivik
JTJ Trovik
J Trovik
HSH B Salvesen
H B Salvesen
Background: Methods: Results: Conclusion:

22 September 2009 in APMIS
Verified
Journal Article
Closed access
PDF file
IEIngeborg B Engelsen
Ingeborg B Engelsen
LALars A Akslen
Lars A Akslen
HSHelga B Salvesen
Helga B Salvesen

1 December 2004 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
HSHelga B. Salvesen
Helga B. Salvesen
ISIngunn Stefansson
Ingunn Stefansson
EKEllen I. Kretzschmar
Ellen I. Kretzschmar
PGPaula Gruber
Paula Gruber
NMNicola D. MacDonald
Nicola D. MacDonald
SDSoma Das
Soma Das
Mutations in the PTEN gene are frequent in endometrial carcinoma. PTEN methylation is an alternative mechanism of gene inactivation. To elucidate different mechanisms of PTEN gene inactivation, we have studied a population-based series of endometrial carcinomas for PTEN mutations in relation to clinicopathologic characteristics, promoter methylation and protein expression. PTEN mutations were found in 54%, mainly in exons 5 and 8; with at least two different mutations in 21%. Presence of PTEN mutation was significantly correlated with young age, low FIGO-stage, endometrioid subtype, low grade, microsatellite instability and favourable prognosis. Previous studies of these tumours have observed PTEN methylation in 18% and low protein expression in 20%. Low expression of PTEN-antibody 6H2.1 was correlated with the presence of mutations in exon 8 among patients with 'two hits'; i.e. > or =2 mutations, or mutation(s) plus methylation (p=0.001). Number of PTEN hits was significantly associated with microsatellite instability, low hMLH1 expression and hMLH1 methylation. Thus, PTEN mutations are frequent in sporadic endometrial carcinoma and define a prognostically favourable subgroup, whereas the relationship with PTEN protein expression is complex. A pathway in endometrial carcinogenesis involving PTEN mutation and microsatellite instability is confirmed, and this study also indicates the importance of PTEN and hMLH1 methylation in this pathway.